研究单位：[1]Zensun Sci. & Tech. Co.,Ltd.[2]The Third People's Hospital of Yunnan Province Kunming,Yunnan,China,650011[3]The Second Hospital of Kunming Medical College Kunming,Yunnan,China[4]Shulan (Hangzhou) Hospital Hangzhou,Zhejiang,China,310000[5]Taizhou Hospital of Zhejiang Province Linhai,Zhejiang,China[6]Quzhou people's hospital Quzhou,Zhejiang,China[7]Fourth Affiliated Hospital of Xinjiang Medical University Xinjiang,Xinjiang,China,830054[8]Wuqing pepole's hospital Tianjing,Tianjing,China,300000[9]The Second People's Hospital of Neijiang Neijiang,Sichuan,China
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
